Navigation Links
Acclarent, Inc. Completes Office-Based Study Using Balloon Sinuplasty(TM) Technology
Date:6/24/2009

MENLO PARK, Calif., June 25 /PRNewswire/ -- Acclarent, Inc., a leading medical technology company dedicated to designing, developing, and commercializing products that address conditions affecting the ear, nose and throat (ENT) today announced the completion of a study evaluating the treatment of patients with Balloon Sinuplasty(TM) technology in the office setting. The prospective, multi-center comparative study evaluated the safety, effectiveness, and cost of performing sinus surgery in the office versus in a hospital operating room setting.

"We are very pleased to have completed this study demonstrating that physicians can successfully treat patients in the office setting using our enabling technology," said Bill Facteau, President and CEO of Acclarent. "We look forward to partnering with physicians in delivering quality, cost-effective healthcare in the office, which offers the potential for significant savings for our healthcare system."

About Acclarent

Acclarent is a global medical technology company dedicated to the development of innovative products to further meet the needs of ENT surgeons and their patients.

Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices. With the Balloon Sinuplasty(TM) technology and our Relieva(R) product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel technologies in all areas of ENT. Acclarent markets and sells its products worldwide and our technology has been used by thousands of physicians.

For more information about Acclarent, visit www.Acclarent.com.


'/>"/>
SOURCE Acclarent, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Acclarent, Inc. Closes $26 Million Financing
2. Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies
3. Acclarent, Inc. Awarded Red Herring 100 North America
4. Eligard(R) six-month formulation successfully completes European approval procedure
5. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
6. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
7. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
8. GSI Securitization Completes Merger and Domicile Transfer
9. Medical Services International Inc. Completes Testing for European Union (EU) Application
10. Inverness Completes Acquisition of Cholestech
11. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Getting breast implants is a choice, but deciding ... to medical necessity. Either way, women should know what to ... says Robert Kraft, MD, Plastic Surgeon with Advanced Dermatology, ... performed each year in the United States, according to the ... procedures stem from three main problems: the breast implant has ...
(Date:7/22/2014)... A new and technologically unique procedure called ... that are surprising even the most skeptical plastic surgeons. ... radio frequency, ThermiTight has been dubbed “InjectableRF” because it ... to “inject” heat to the tissues which cause sagging ... solution for skin laxity produces results in weeks, with ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 On Monday, September ... Charity Golf Outing honoring Mike McGuriman-Motorola Solutions at The Knoll ... outing begins with registration and lunch at 11 a.m. ... and prizes. Price increases to $250 after September 7th. ... for $100 per person. The dinner will include a ...
(Date:7/21/2014)... MINNEAPOLIS, Minnesota (PRWEB) July 21, 2014 ... on providing service, support, education, and add-ons for ... Microsoft Dynamics Inner Circle, an elite group of ... the globe with sales achievements that rank them ... global network of partners. Members of the Microsoft ...
(Date:7/21/2014)... It,s human nature to hate losing. , Unfortunately, ... potentially abandoning a solid strategy and thus increasing your ... one conclusion of a Brigham Young University study published ... The finding is based on an analysis of two ... researchers focused on whether coaches adjusted their personnel following ...
Breaking Medicine News(10 mins):Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 2Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 3Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2
... , CHICAGO, Sept. 1 In ... which shows young athletes with repeated brain injuries are at ... Association (IATA) and the Chicago Institute of Neurosurgery and Neuroresearch ... and monitoring concussions. The complimentary card is an educational tool ...
... , , , FRANKLIN LAKES, N.J., Sept. 1 ... announced today that it would present at the following investor healthcare conferences in September: , ... September 9, 2009, ... Conference, September 14, 2009, ...
... than laparoscopic surgery, study finds , TUESDAY, Sept. 1 ... pelvic pain by disrupting nerve connections failed to improve ... researchers say. , The nerve-disruption procedure "did not alleviate ... irrespective of the presence or absence of mild endometriosis," ...
... , , WARSAW, Ind., Sept. 1 Zimmer ... be participating in the following investor conferences during the month of September: , ... Conference 2009 in Boston, Mass., on September 9, 2009, at 11:30 a.m. Eastern ... New York, N.Y., on September 14, 2009, at 8:35 a.m. Eastern Time; and ...
... "Saturday ... Dr. Lonnie Paulos now beginning its second year , ... Gulf Breeze, FL (Vocus) September 1, 2009 -- ... orthopaedic exams and assessments to high school and collegiate athletes on Saturday mornings. ...
... , KANSAS CITY, Mo., Sept. 1 ... with medical challenges often unique to members of the military. From ... some of the most pressing conditions confronting the health care system ... Release, go to: http://www.prnewswire.com/mnr/militaryhealth/39824/ , ...
Cached Medicine News:Health News:Illinois Athletic Trainers and Physicians Offer Handy Wallet Card to Tackle Concussions 'Head On' 2Health News:Two Treatments Equally Effective for Chronic Pelvic Pain 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 3Health News:Video: Physical and Mental Health of U.S. Warfighter Is Focus of Military Health Research Forum 2
(Date:7/21/2014)... 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... Administration (FDA) accepted the company,s Investigational New Drug (IND) ... and efficacy of AVP-786, Avanir,s next generation compound. The ... the adjunctive treatment of major depressive disorder (MDD) during ... "The endorsement of this Phase II study by the ...
(Date:7/21/2014)... , July 21, 2014 Sorrento Therapeutics, ... clinical oncology company developing new treatments for cancer and ... non-dilutive funding for the preclinical development of a small ... The Myc protein has also been ... protein synthesis. It is involved as a dominant factor ...
(Date:7/21/2014)... 21, 2014   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting ... Drug Administration (FDA) has granted orphan drug designation ... that binds to and inhibits the function of ... of Alport syndrome, a life-threatening genetic kidney disease ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) ... in a Phase 2 clinical trial using intravenous ... carboplatin in patients with non-small cell lung cancer ... Investigator is Dr. Miguel Villalona-Calero, Professor, Division of ...
... The following is being issued by Coast IRB: ... 2009, Coast IRB informed the public that it had discovered ... that Independent review board for evaluation. Coast IRB has ... part of a congressional "sting" operation. Apparently at the ...
Cached Medicine Technology:Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2Congressional 'Sting' Operation Uncovered By Coast IRB 2
These retractors are packaged singly ready for sterilization at your facility....
... is a revolutionary motorized electronic pipette. ... mind, Pipetman Concept features exclusive multifunction ... only one of its kind in ... Tips from Gilson, this product will ...
Rainbow technology combines the latest in system theory, adaptive signal processing and a revolutionary sensor that employs eight wavelengths of light to collect and analyze an extraordinarily rich s...
... is a revolutionary motorized electronic pipette. ... mind, Pipetman Concept features exclusive multifunction ... only one of its kind in ... Tips from Gilson, this product will ...
Medicine Products: